Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0025202 (melanoma)
 69,561 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

BCG has successfuly been applied in lymphoid and in myeloid leukemia but no positive results have been demonstrated in solid tumors except malignant melanoma after intratumoral injection. The authors' approach consists in applying BCG as an only antitumor treatment, much smaller doses and in much longer intervals between them than used by other investigators. The analysis of the treatment schemes of BCG, applied to 171 lung cancer patients showed that positive responses have been obtained only in patients without peripheral dissemination of the disease and that in doses from 0.0001 mg to 0.05 mg. The results obtained depended on the frequency of BCG application: the 5 years survival rate, the mean survival period and the rate of the marked X-ray regression have been found best in patients treated once, good in patients treated in intervals longer than 30 days between the applications of the mycobacteria and worse in patients treated in intervals shorter than 20 days. A direct inverse correlation has been discovered between the mean survival period of the treated patients and the number of the applications of BCG in the first 6 months of the treatment.
 ...
PMID:Analysis of the results of treament of lung cancer patients with BCG according to the scheme of application of the bacillus. 32 24

In a phase II trial, prednimustine was often efficient in treating chronic lymphoid leukaemia (CLL) patients and was also active in some patients with lymphosarcoma, melanoma and bronchus carcinoma. Tolerance was generally excellent, the most critical side effect being thrombocytopenia in the case of CLL.
 ...
PMID:A phase II clinical trial of prednimustine. Clinical screening cooperative group of E.O.R.T.C. 32 10

A total alkaloid and two purified alkaloid extracts of Alangium Vitiense were revealed by our experimental screening to be oncostatic on L1210 leukemia and two other lymphoid neoplasias in Mice. They are not active on myelomonocytoid leukemia WEHI3 nor on B16 melanoma.
 ...
PMID:[Oncostatic activity of extracts from Alangium vitiense on murine lymphoid neoplasms]. 41 57

The effects of a single immunization of melanoma patients with BCG or C. parvum on the blood counts, serum immunoglobulin levels and lymphoid subpopulations were followed by multiple assays over 28 days. C. parvum produced a decrease in the white cell count, lymphocyte count and lymphoid T and sIg+ cell numbers, which recovered within 1 week; BCG did not produce such a marked depression. Both agents were associated with increases in T cell numbers and lymphocyte PHA blastogenesis after the first week; these declined to pre-immunization values by 3-4 weeks. The sIg-bearing cell subpopulation also increased after BCG. Different methods of expression the results were compared and the difficulties of immunological monitoring are discussed.
 ...
PMID:Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma a sequential study over 28 days. I. Changes in blood counts, serum immunoglobulins and lymphoid cell populations. 42 46

11 cultured human melanoma cell lines were tested for the expression of DR antigens by using specific allo- and xenoantisera in an indirect rosette microassay. Four of these melanoma cell lines expressed DR antigens, but in lower amounts than expressed on cultured human B-lymphoid cells. Rabbits injected with the DR-positive melanoma cells produced antibodies that were serologically and immunochemically reactive with B-cell-derived DR antigens. Immunochemical studies indicate that melanoma cell-derived DR antigens have a two-chain structure with 34,000 and 27,000 mol wt components. The melanoma cell-derived DR beta-chain at 27,000 mol wt is slightly smaller than that of the Victor cell DR beta-chain whose mol wt is 29,000.
 ...
PMID:DR (Ia-like) antigens on human melanoma cells. Serological detection and immunochemical characterization. 42 61

The effect of neonatal thymus grafts implanted in nude mice previously transplanted with three different human malignant tumors - an adenocarcinoma of the colon, a malignant melanoma and a Burkitt's lymphoma - were studied. In all immunologically reconstituted animals tumord were rejected. Tumor rejection stated 2-3 weeks after thymus implantation, and was completed after 30-6 weeks. Histological examination of lymphoid tissues showed a correlation between immunological reconstitution and tumor rejection. The rejection process showed a characteristic histologic picture with 3 phases - an early, an intermediate and a late phase - these were similar in the three tumor types examined. The possible mechanisms of reconstitution and tumor rejection are discussed.
 ...
PMID:Effects of thymus grafts in nude mice transplated with human malignant tumors. 52 Jun 48

The antiblastomic activity of the carminomycin complex components was studied with respect to 8 strains of transplantable tumors of mice: lymphosarcoma L10-1, prestomach cancer OZh-5, sarcoma 180, lymphoid leucosis L 1210, lung bronchogenic cancer RL, lymphodenosis NK/LI, Ehrlich carcinoma and Garding-Passy melanoma. It was shown that components I, II and III possessed almost the same high antiblastomic activity and the same optimal administration schemes should be used for them. The scheme consisted of two-fold administration of the drug at intervals of 96-120 hours. Component I had broader therapeutic ranges and was more active against the lung bronchogenic cancer as compared to component II. All 3 components had no selective antiblastomic effect on the ascitic form of Ehrlich carcinoma. A comparative study of the component toxicity and pharmacology is required for final conclusion as to the recommendation of one of the components for clinical trials.
 ...
PMID:[Antitumor activity of the components of a carminomycin complex]. 57 73

A total alkaloid and two purified alkaloid extracts of Alangium vitiense were found to be oncostatic for L1210 leukemia; the total alkaloid exerted a noticeable activity, and the purified extracts exerted a borderline activity. These two purified extracts are noticeably oncostatic for two other lymphoid neoplasias in mice, P388 leukemia and Gardner lymphosarcoma. These compounds are not active on Warner myelomonocytic leukemia WEH13 or on B16 melanoma.
 ...
PMID:Oncostatic effects of Alangium vitiense extracts (ICIG-EORTC 1131, 1186 and 1207) on lymphoid murine tumors. 58 Apr 15

Sixteen patients with disseminated melanoma were immunised with either BCG (8 cases) or C. parvum (8 cases) on three occasions at 21 day intervals. Blood for assay was taken immediately before the first immunisation and weekly for eight weeks thereafter. Total white count tended to increase but little change was seen in lymphocyte and monocyte counts. Serum IgG increased after BCG BUT NOT WITH C. parvum, serum IgA and IgM did not alter. The 'E' rosette % did show some increase mainly after C. parvum, and 'B' lymphoid cells (sIg staining) increased slightly after BCG; the 'EA' rosette % fell following C. parvum but not after BCG. Lymphocyte PHA blastogenesis increased after immunisation, particularly with BCG. Non-specific lymphocytotoxicity (51 Cr Chang target) demonstrated dramatic increases for 'non T' and 'K' cell function and a smaller increase in 'T' cell cytotoxicity following immunisation. These increases in cytotoxicity were maintained by the 21 day immunisation schedule.
 ...
PMID:Effects of BCG and Corynebacterium parvum on immune reactivity in melanoma patients. 60 36

The effect of immune RNA treatment on the incidence of death from pulmonary metastases was studied in C57BL/6J mice after excision of a B16 murine melanoma. Immune RNA was extracted from the lymphoid tissues of guinea pigs immunized with B16 tumor and then incubated in vitro with normal C57BL/6J mouse splenocytes. Mice receiving intraperitoneal injections of these RNA-treated syngeneic splenocytes after the primary B16 isograft was resectioned showed significantly improved long-term survival (42 to 67 percent in three successive experiments) as compared to control mice (0 to 20 percent survival) receiving untreated splenocytes. The effect of RNA treatment was tumor-specific and ribonuclease sensitive. The results suggest that immunotherapy with immune RNA may be of benefit to certain patients after surgery for cancer.
 ...
PMID:Prevention of death from metastases by immune RNA therapy. 69 19


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>